DREADDs: a receptor built to order
Chemogenetics is the molecular write channel that actually works at scale in neuroscience. A DREADD — a Designer Receptor Exclusively Activated by a Designer Drug — is a mutated G-protein-coupled receptor engineered to ignore native ligands and respond only to an otherwise-inert compound (clozapine-N-oxide and its cleaner successors). Express the DREADD in a chosen cell population, give the drug, and you excite or silence exactly those cells.
The strengths are real and specific: genetic targeting to a cell type, no implanted hardware, whole-structure coverage from a single systemic dose, and a growing toolkit including excitatory, inhibitory and G_q/G_i/G_s-coupled variants, plus the ligand-side details of DREADD actuator pharmacology. It is the workhorse of causal circuit neuroscience.
The pharmacological clock
Now the fundamental limit. A drug must be absorbed, cross into the brain, bind the receptor, and later clear. Onset and offset are therefore governed by pharmacokinetics, not by neural timescales — minutes to hours, not milliseconds. Chemogenetics is a tonic dial on excitability, not a way to write a spike train.
First-order clearance of the actuator drug. The clearance time τ_clear (minutes to hours) — not any neural time constant — sets how quickly a chemogenetic manipulation turns on and off.
Receptor occupancy θ follows a Hill relation in ligand concentration C, with affinity K_d and cooperativity n. The effect tracks a smooth dose–occupancy curve, reinforcing that chemogenetics modulates a level rather than delivering timed events.
Faster switches and other actuators
To recover speed, molecular engineers turn to light-gated chemistry. A chemical photoswitch is a small molecule tethered to a native receptor or channel that changes shape under light — millisecond control with pharmacological specificity, at the cost of reintroducing the light-delivery problem. Chemogenetic ion channels (PSAM/PSEM) give ionotropic, faster-than-GPCR control while keeping the designer-ligand logic.
A separate frontier is delivery itself. Focused-ultrasound blood–brain-barrier opening can transiently and non-invasively let a vector or drug into a targeted region — a physical key that could make chemical and genetic writing far more practical without surgery. It is advancing in trials but is not yet routine, and safety margins around the barrier disruption are still being characterised.